Anzeige
Mehr »
Login
Freitag, 22.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PZ5J | ISIN: NO0010714785 | Ticker-Symbol: 5VB
München
21.11.24
08:06 Uhr
0,240 Euro
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
NYKODE THERAPEUTICS ASA Chart 1 Jahr
5-Tage-Chart
NYKODE THERAPEUTICS ASA 5-Tage-Chart

Aktuelle News zur NYKODE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiNYKODE THERAPEUTICS ASA: Nykode Therapeutics - invitation to Q3 2024 financial results presentation2
08.11.In 'surprise' termination, Genentech drops Nykode partnership for individualized cancer vaccine31
08.11.Nykode Therapeutics ASA - Mandatory Notification of Trade by Closely Associated Party of a Primary Insider3
NYKODE THERAPEUTICS Aktie jetzt für 0€ handeln
08.11.Disclosure of large shareholding in Nykode Therapeutics ASA3
07.11.Nykode Therapeutics To Regain Control Of VB10.Neo Program3
06.11.Nykode Therapeutics ASA: Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at PEGS Europe5
27.09.NYKODE THERAPEUTICS ASA: Major shareholding notification2
21.08.NYKODE THERAPEUTICS ASA: Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider5
14.08.Nykode Therapeutics ASA: Nykode Therapeutics Announces Issuance of Key Patent Covering Individualized Neoantigen Based Vaccines189OSLO, Norway, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies...
► Artikel lesen
01.08.Nykode Therapeutics ASA: Nykode Therapeutics - invitation to Q2 2024 financial results presentation2
20.06.Nykode Therapeutics ASA: Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at FOCIS 2024 Meeting4
11.06.Nykode Therapeutics ASA: Nykode Therapeutics Announces mRNA-LNP Cancer Vaccine Demonstrates Superior Efficacy353OSLO, Norway, June 11, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies...
► Artikel lesen
19.04.Nykode Therapeutics ASA: Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer680OSLO, Norway, April 19, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies...
► Artikel lesen
08.04.DelveInsight Business Research, LLP: HPV16+ Cancer Treatment Market is Expected to Showcase Significant Growth by 2034, Assesses DelveInsight | Key Companies in the Market - Nykode Therapeutics, Roche, ISA Pharmaceuticals, Regeneron, Transgene1.221The HPV 16+ cancer market size is anticipated to increase due to an increase in the research and development programs related to HPV 16+ cancer in recent years. Future research requires focusing...
► Artikel lesen
21.03.Nykode Therapeutics ASA: Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer159Updated survival data from Phase 2 trial (C-02) in advanced cervical cancer affirm prolonged benefits and indicate a synergistic treatment effect of Nykode's VB10.16 and atezolizumab (Tecentriq®).New...
► Artikel lesen
19.03.Nykode Therapeutics ASA: Nykode Therapeutics Announces Advances in the Inverse Vaccine Platform With the Potential to Treat Autoimmune Diseases309OSLO, Norway, March 19, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies...
► Artikel lesen
16 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1